跳转至内容
Merck
CN

SML3584

Sigma-Aldrich

AZ1

≥98% (HPLC)

别名:

2-[[[5-Bromo-2-[[4-fluoro-3-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]amino]-ethanol, AZ 1, AZ-1

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C17H16BrF4NO2
分子量:
422.21
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.21

质量水平

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

2-8°C

SMILES字符串

FC1=CC=C(COC2=CC=C(C=C2CNCCO)Br)C=C1C(F)(F)F

InChI key

ITHSFXDGKQYOED-UHFFFAOYSA-N

生化/生理作用

AZ1 is a potent and selective dual USP25 & USP28 deubiquitinase (DUBs) inhibitor (USP25/28 IC50 = 0.62/0.7 nM by Ub-Rh110 assay) that induces HCT116 cellular c-Myc degradation (20-100 µM for 3h or 60 µM for 0.3-3h). AZ1 exhibits antiproliferation activity in cancer cultures (IC50 ≤20 µM; HCT116, HT29 and SW480) and anti-tumor efficacy in an orthotopic model of lung SCC tumours in mice in vivo (125 mg/kg or 375 mg/kg i.p. once every three days, 6 injections total).
Potent and selective dual USP25 & USP28 deubiquitinase (DUBs) inhibitor with anti-cancer efficacy in vitro and in vivo.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

The deubiquitinase USP25 supports colonic inflammation and bacterial infection and promotes colorectal cancer
Nature cancer, 1, 811-825 (2020)
Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells
Oncogene, 39, 3867-3878 (2020)
Inhibition of USP28 overcomes Cisplatin-resistance of squamous tumors by suppression of the Fanconi anemia pathway
Cell Death and Differentiation, 29, 568-584 (2022)
Maintaining protein stability of ?Np63 via USP28 is required by squamous cancer cells
Cristian Prieto-Garcia, Oliver Hartmann, Michaela Reissland, Fabian Braun, Thomas Fischer
EMBO Molecular Medicine, 12 (2022)
USP28 enables oncogenic transformation of respiratory cells, and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K
Molecular Oncology, 16, 3082-3106 (2022)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门